- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02882360
Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum
August 24, 2016 updated by: Debbie Penava, Lawson Health Research Institute
The Use of Antimicrobial Gauze in Pregnant Women Undergoing C-section With BMI >40 to Decrease Wound Complications by 6 Weeks postpartum--a Small Feasibility Study
Pregnant women with BMI>40 will be approached for participation in a study to reduce the rate of post-operative wound infection from C-section.
Women will be randomized to a commonly used wound product (Kerlix-AMD) which consists of a PHMB-impregnated gauze versus normal gauze, and rates of post-operative surgical site infection will be assessed.
Women with a planned procedure will also be randomized to applying Kerlix versus gauze for 3 days pre-operatively to determine if this improves outcomes as well.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study be a randomized double-blinded feasibility study to improve the rates of wound complications post-C/S in women with a BMI >40.
It will be conducted out of a single tertiary care centre in London, Ontario.
The women will be randomized to one of two treatment groups, either Kerlix AMD gauze or Kerlix plain gauze (Kendall, Covidien AG, Mansfield MA).
This randomization will be performed by validated computer based randomization software (www.sealedenvelope.com).
The patients, staff and physicians will be blinded to the assigned groups.
After consenting to the study, at the time of their C/S, participants will be assigned a sealed envelope which will contain their assigned group.
All patients with a BMI >40 who qualify for the study that are seen in the outpatient clinics at our centre will be approached about their participation in the study.
Patients that meet the study criteria who are seen for the first time after being admitted to the labor and delivery ward will be consented for the study, and if they do not require a C/S, then this consent will be disregarded.
Participants who have a planned C/S will also be randomized to receive treatment with either AMD or plain gauze for three days prior to their C/S.
This requires placement of a piece of gauze, randomly assigned, under the pannus in the area of the anticipated incision.
This gauze is to be changed daily for three days prior to the booked C/S.
These patients will continue to receive the same gauze they were assigned to post-operatively.
As part of routine care peri-operatively, all patients receive 3g of Ancef 15-60 min prior to skin incision (Ayres-de-Campos), and their skin is prepped with 2% chlorohexidine (Lee I) (2%, Laboratoire Atlas Inc, Montreal, QC) .
The subcutaneous layer will be closed at the end of the case using absorbable sutures (Chelmow).
The skin will be closed with a running absorbable suture in the subcuticular layer (Clay).
At the end of the C/S, all patients will have their respective gauze placed over their incision, with a Tegaderm (3M Healthcare, St. Paul, MN) or pressure dressing placed on top.
This outer occlusive dressing will be removed poat-operative day )POD) 1, unless it becomes saturated before then.
Their gauze will be replaced daily, or more frequently if it becomes saturated.
The incisions will be inspected daily by a physician while they are in hospital.
The Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria will be used to diagnose wound infections.
They will be discharged home with enough gauze for daily dressing changes for two weeks, as well as an information sheet outlining signs and symptoms to be aware of, or reasons to return to hospital.
Their incision will be inspected by a physician at one, two and six weeks post-operatively.
If at any point over the duration of the study they develop signs or symptoms of infection or any other complications, they will be investigated and treated accordingly.
This may involve taking a picture of the wound to track whether or not cellulitis or infection is spreading or tracking; this will always be with your explicit consent and to track wound progression.
At six weeks they will also complete a qualitative survey investigating their subjective experience with the gauze and the protocol.
A cost analysis will also be performed.
All data will be collected using data collection sheets.
The newest version of Statistical Package for Social Sciences (SPSS) Statistical analysis software will be used to conduct data analysis, using formulas such as student t-test for continuous data and chi-squared for nominal data.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Debbie Penava, MD
- Phone Number: 5196466401
- Email: Debbie.Penava@lhsc.on.ca
Study Contact Backup
- Name: Jennifer Ryder, HBSc, MHS
- Phone Number: 519-685-8781
- Email: Jennifer.Ryder@lhsc.on.ca
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 50 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- pregnant women at LHSC with BMI >40
Exclusion Criteria:
- pregnant women who cannot understand English, who have a fetal demise or who have a pre-existent infected skin infection at the site of c-section
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elective LSCS--Kerlix AMD
Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
|
Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS.
Gauze to be changed daily or more frequently if damp/blood-tinged
|
Placebo Comparator: Elective LSCS--Placebo
Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
|
Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS.
Gauze to be changed daily or more frequently if damp/blood-tinged
|
Experimental: Labouring LSCS--Kerlix AMD
Kerlix-AMD applied to wound post-operatively for 2 weeks
|
Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS.
Gauze to be changed daily or more frequently if damp/blood-tinged
|
Placebo Comparator: Labouring LSCS--Placebo
Normal gauze applied to wound post-operatively for 2 weeks
|
Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS.
Gauze to be changed daily or more frequently if damp/blood-tinged
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
surgical site infection
Time Frame: 6 weeks
|
All patients will have their wounds assessed by 6 weeks post partum to evaluate for the presence (or absence) of surgical site infection, using the Centers for Disease Control and Prevention (CDC) Nosocomial Infections Surveillance (NNIS) system criteria.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
patient satisfaction
Time Frame: 6 weeks
|
patients will be surveyed on adherence and acceptability of application of gauze post c-section
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Debbie Penava, MD, Lawson Health Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2016
Primary Completion (Anticipated)
January 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
May 12, 2016
First Submitted That Met QC Criteria
August 24, 2016
First Posted (Estimate)
August 29, 2016
Study Record Updates
Last Update Posted (Estimate)
August 29, 2016
Last Update Submitted That Met QC Criteria
August 24, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 106708
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Kerlix-AMD
-
Lucy A WibbenmeyerMedtronic - MITGCompletedBurns | WoundsUnited States
-
Tainan Municipal HospitalCompleted
-
i-Lumen Scientific, Inc.WithdrawnDry Age-related Macular Degeneration
-
i-Lumen Scientific, Inc.RecruitingAge-Related Macular Degeneration | Dry Age-related Macular Degeneration | Nonexudative Age-related Macular DegenerationUnited States
-
Sequenom, Inc.CompletedAge-related Macular DegenerationUnited States
-
Notal Vision Ltd.CompletedAge Related Macular DegenerationUnited States
-
The New York Eye & Ear InfirmaryiHealthScreen IncRecruiting
-
Icahn School of Medicine at Mount SinaiUniversity of California, Los Angeles; National Eye Institute (NEI)Recruiting
-
Osaka UniversityHuman Genome Center, Institute of Medical Science, University of TokyoCompletedAge Related Macular Degeneration | Neovascular MaculopathyJapan